 Home > Medical News > Latest Medical News > ALK-1 monoclonal antibody/Opdivo combination for first-line treatment of advanced liver cancer is clinically approved in China

ALK-1 monoclonal antibody/Opdivo combination for first-line treatment of advanced liver cancer is clinically approved in China

 Last Update: 2021-10-21
 Source: Internet
 Author: User

Tags

concerta drug

aurobindo pharma recalls

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Pioneer Pharmaceuticals announced that the National Medical Products Administration (NMPA) of China has recently approved its ALK-1 monoclonal antibody (GT90001C), and Bristol-Myers Squibb's (BMS) anti-PD-1 monoclonal antibody nivolumab (English trade name Opdivo) Combined clinical trial for the treatment of patients with advanced hepatocellular carcinoma (HCC) who have not been systemically treated

Liver cancer is the fourth most common cancer in China and the second most fatal cancer.

The Phase 2 clinical trial of ALK-1 monoclonal antibody/nivolumab combination therapy for the second-line treatment of patients with advanced hepatocellular carcinoma was first launched in 2019

Reference materials:

[1] Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma.

[2] The clinical trial of the first-line treatment of advanced hepatocellular carcinoma with the combination of ALK-1 monoclonal antibody and O drug by Kaixing Pharmaceutical was approved by the China Food and Drug Administration.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express first-line treatment of advanced liver cancer, ALK-1 monoclonal antibody/Opdivo combination is clinically approved in China

10-21

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

ALK-1 monoclonal antibody/Opdivo combination for first-line treatment of advanced liver cancer is clinically approved in China

Related Articles

Express first-line treatment of advanced liver cancer, ALK-1 monoclonal antibody/Opdivo combination is clinically approved in China